Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease. Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

To compare the gene expression of these groups before OCA treatment in responders with therapeutic effect on OCA and non-responders without therapeutic effect, mRNA-seq was performed on liver biopsy samples before OCA administration. Overall design: Comparison of RNA-seq data from liver biopsy of OCA responder, non-responder, and vehicle *** Raw data has been lost and thus is not provided ***